Immediate Release

DIMERIX RECEIVES R&D TAX REBATE TOTALLING $7.9 MILLION

- Enhanced cash position with receipt of $7.9 million R&D Tax Incentive rebate for the 2023/2024 financial year
- ACTION3 Phase 3 clinical trial continues to progress well
- Part 2: Interim analysis anticipated around mid-2025 calendar year[1]

MELBOURNE, Australia, 15 November 2024: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to advise that the Company has received its Research and Development (R&D) Tax Incentive rebate for the 2023/2024 financial year amounting to $7,932,428.15.

"We greatly appreciate the support of the Australian Government with this invaluable incentive, as Dimerix advances DMX-200 towards potential commercialisation. This rebate will be applied to progressing the Company's lead global Phase 3 clinical program in FSGS kidney disease patients, and further supports the Company's existing strong cash position."

Dr Nina Webster, CEO & Managing Director, Dimerix

The R&D Tax Incentive program is the government's key mechanism to stimulate Australian industries investment in R&D, encouraging companies to engage in R&D benefiting Australia, by providing a tax offset equal to the entity's company tax rate (currently being 25% for Dimerix) plus an 18.5% premium for eligible entities with an aggregated turnover of less than $20 million per annum.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on LinkedIn and Twitter

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for respiratory disease. DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About ACTION3 FSGS Phase 3 Study

The Phase 3 study, which is titled **"A**ngiotensin II Type 1 Receptor (AT1R) & **C**hemokine Receptor 2 (CCR2) **T**argets for **I**nflammat**o**ry **N**ephrosis", or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX200 (120 mg capsule twice daily) or placebo.

The single Phase 3 trial in FSGS patients has interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval.

Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

---

[1] *Subject to recruitment*